Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized medicine in cystic fibrosis: dawning of a new era.

American journal of respiratory and critical care medicine - 1 Oct 2012

Clancy John P, Jain Manu

Abstract excerpt

Life expectancy in cystic fibrosis (CF) has improved substantially over the last 75 years, with a median predicted survival now approaching 40 years. This improvement has resulted largely from therapies treating end-organ manifestations. In an effort to develop drugs that would target the underlying defects in the CF transmembrane conductance regulator (CFTR), the Cystic Fibrosis Foundation embarked on a bold...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CFTR gene

Share to Mutation

Share to Precision Medicine

Source

Identifiers

PMID: 22723294
DOI: 10.1164/rccm.201204-0785PP

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized medicine in cystic fibrosis: dawning of a new era.PMID 22723294Read ↗

Cystic fibrosis in an era of genomically guided therapy.Semantic proximity Read ↗

The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?Semantic proximity Read ↗

Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients.Semantic proximity Read ↗

Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies.Semantic proximity Read ↗

A new era of personalized medicine for cystic fibrosis - at last!Semantic proximity Read ↗

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.Semantic proximity Read ↗

A personalized medicine approach to optimize care for a pediatric cystic fibrosis patient with atypical clinical symptomsSemantic proximity Read ↗

New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.Semantic proximity Read ↗

Precision Medicine Based on CFTR Genotype for People with Cystic FibrosisSemantic proximity Read ↗

Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.Semantic proximity Read ↗

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR GenotypeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.